Show Summary Details
Page of

Chronic medical therapy and the GOLD guidelines 

Chronic medical therapy and the GOLD guidelines
Chapter:
Chronic medical therapy and the GOLD guidelines
Author(s):

Miguel Carrera

, Ernest Sala

, and Alvar GN Agustí

DOI:
10.1093/med/9780199549146.003.0006
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 14 December 2017

Active reduction of risk factors and bronchodilator treatment are central to the management of COPD.

Regular use of long-acting bronchodilators (β‎2-agonists and antimuscarinics) is more effective than short-acting bronchodilators in patients with persistent symptoms.

Inhaled corticosteroids (ICS) combined with bronchodilators are indicated in patients with forced expiratory volume in 1s FEV1 < 50% predicted and repeated exacerbations.

Influenza vaccination is indicated for all COPD patients; while pneumococcal vaccine is recommended for COPD patients older than 65 years, and in those younger with FEV1 < 40% predicted.

Antibiotics should only be used for infectious exacerbations of COPD, while N-acetylcysteine only affects the frequency of exacerbations in patients off inhaled corticosteroids.

Mucolytic agents, antitussives, and vasodilators are not recommended in stable COPD.

All COPD patients benefit from exercise training programmes, while long-term oxygen therapy increases survival in COPD patients with chronic respiratory failure.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.